LNG/EE

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Vertex Pharmaceuticals Incorporated

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)HIV Pre-Exposure ProphylaxisHuman Immunodeficiency Virus (HIV)

Phase 1

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

CompletedNCT06783192

Merck Sharp & Dohme LLCHuman Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis

Start: 2023-08-14End: 2023-10-11Updated: 2025-01-20

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

CompletedNCT07074327

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2025-07-11End: 2026-02-27Updated: 2026-03-30

Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Not yet recruitingNCT07792408

Vertex Pharmaceuticals IncorporatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)

Start: 2026-08-28End: 2027-03-20Target: 148Updated: 2026-08-28